SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the leader in continuous glucose monitoring (CGM) for people with diabetes, today announced a development agreement with Eli Lilly and Company (NYSE: LLY) to include Dexcom CGM into Lilly’s Connected Diabetes Ecosystem. The companies expect to combine Lilly’s smart insulin delivery devices and Dexcom CGM to improve the future of diabetes management.
“Lilly’s Connected Diabetes Ecosystem promises to drive a significant step forward in diabetes management. As technology converges in our industry, we believe that connected systems will become the standard of care over time,” said Kevin Sayer, President and CEO of Dexcom. “By combining devices, drugs and technology, we can deliver solutions that adapt to each person’s unique needs in managing their diabetes while also providing compelling advancements for both physicians and payers.”
Through the Connected Diabetes Ecosystem, the companies aim to provide a comprehensive solution to people with diabetes. Devices such as CGM, smart-pens and insulin pumps, drugs, apps and other analytical tools will be aimed at improving outcomes. Clinical trials are expected to begin by the end of 2017.
“The Connected Diabetes Ecosystem relies not only on Lilly’s core diabetes expertise, but also the strength of our key partners such as Dexcom,” said Enrique Conterno, president, Lilly Diabetes and Lilly USA. “Dexcom will be an important collaborator in our mission to improve outcomes and reduce the daily burden for people with diabetes.”
About DexCom, Inc. (NASDAQ: DXCM)
DexCom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) products and tools for adult and pediatric patients. With exceptional performance, patient comfort and lifestyle flexibility at the heart of its technology, users have consistently ranked Dexcom highest in customer satisfaction and loyalty. For more information, visit www.dexcom.com.